Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

• Narrative Content
• XML
• JSON
• TTL

: SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer - JSON Representation

Raw json | Download

{
  "resourceType" : "Library",
  "id" : "179618",
  "meta" : {
    "versionId" : "3",
    "lastUpdated" : "2023-11-26T21:01:14.757Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/systematic-review-included-studies"
    ]
  },
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: Library 179618</b></p><a name=\"179618\"> </a><a name=\"hc179618\"> </a><a name=\"179618-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 3; Last updated: 2023-11-26 21:01:14+0000</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-systematic-review-included-studies.html\">SystematicReviewIncludedStudies</a></p></div><h2>Participants</h2><table class=\"grid\"><tr><td>Author</td><td>Brian S. Alper</td></tr></table><h2>Related Artifacts</h2><table class=\"grid\"><tr><td>Derived From</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr><tr><td>Contains</td><td/></tr></table></div>"
  },
  "url" : "https://fevir.net/resources/Library/179618",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net",
      "value" : "179618",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.4.642.40.44.28.3"
    }
  ],
  "version" : "2.0.0-ballot",
  "title" : "SystematicReviewIncludedStudies: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer",
  "status" : "active",
  "type" : {
    "coding" : [
      {
        "system" : "http://terminology.hl7.org/CodeSystem/library-type",
        "code" : "asset-collection",
        "display" : "Asset Collection"
      }
    ]
  },
  "subjectReference" : {
    🔗 "reference" : "Group/179619",
    "type" : "Group",
    "display" : "SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer"
  },
  "date" : "2023-11-26T18:15:27.442Z",
  "publisher" : "HL7 International / Clinical Decision Support",
  "contact" : [
    {
      "name" : "HL7 International / Clinical Decision Support",
      "telecom" : [
        {
          "system" : "url",
          "value" : "http://www.hl7.org/Special/committees/dss"
        }
      ]
    }
  ],
  "description" : "3 included studies",
  "useContext" : [
    {
      "code" : {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "evidence-communication",
        "display" : "Evidence Communication"
      },
      "valueCodeableConcept" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "SystematicReviewIncludedStudies",
            "display" : "SystematicReviewIncludedStudies"
          }
        ]
      }
    }
  ],
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "http://unstats.un.org/unsd/methods/m49/m49.htm",
          "code" : "001",
          "display" : "World"
        }
      ]
    }
  ],
  "copyright" : "https://creativecommons.org/licenses/by-nc-sa/4.0/",
  "author" : [
    {
      "name" : "Brian S. Alper"
    }
  ],
  "relatedArtifact" : [
    {
      "type" : "derived-from",
      "resourceReference" : {
        🔗 "reference" : "Citation/179613",
        "type" : "Citation",
        "display" : "27308831 Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis."
      }
    },
    {
      "type" : "contains",
      "resourceReference" : {
        🔗 "reference" : "Citation/179615",
        "type" : "Citation",
        "display" : "23306100 Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial."
      }
    },
    {
      "type" : "contains",
      "resourceReference" : {
        🔗 "reference" : "Citation/179617",
        "type" : "Citation",
        "display" : "25301760 Survival with Newly Diagnosed Metastatic Prostate Cancer in the 'Docetaxel Era': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)."
      }
    },
    {
      "type" : "contains",
      "resourceReference" : {
        🔗 "reference" : "Citation/179616",
        "type" : "Citation",
        "display" : "26244877 Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer."
      }
    }
  ]
}